tbuckley/cabot-search huggingface dataset:
J Air Pollut Control Assoc, Pittsburgh
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC).
Authors: Khodadad Rasool Javaheri, Caroline Speers, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2014)

568 Background: While urban-rural differences in cancer care are well described, the etiology for such disparities is unclear. Our aim was to determine whether differences in AC use are mediated through variations in community size (CS) and whether differences in AC use translated into differences in patient survival outcomes (SO). Methods: Patients with stage II/III RC from 1999 to 2009 and referred to any 1 of 5 regional cancer centers in British Columbia were reviewed. Communities were classified as rural (R), small urban (SU), moderate urban (MU), and large urban (LU) based on census data. Using zip codes and a distance matrix application interface, driving distance (DD) to patients’ respective cancer center (CC) was determined and categorized into quartiles. Stepwise logistic regression was used to explore AC use based on urban-rural communities, controlling for DD. Cox regression was used to identify whether variations in CS translated into differences in SO. Results: A total of 2618 patients were identified: median age 67 years (IQR 58-75), 64% men, and 63% received AC. Patients were distributed across various communities: R 37%; SU 11%; MU 13%; and LU 39%. There were no differences in baseline characteristics based on CS (all p&lt;0.05). Compared to patients in LU centers, those living in R, SU and MU areas were less likely to be treated with AC (55 % vs. 49% vs. 71%, respectively, p&lt;0.001). Likewise, DD was shortest for LU and longest for R residents (p&lt;0.001). In multivariate analysis that controlled for confounders, urban-rural disparities in receipt of AC persisted, and these differences were significantly increased after adjusting for DD (Table). In Cox regression analysis which controlled for confounders, patients who lived in R, SU, and MU regions did not have a significantly inferior SO in comparison to those living in LU areas (HR: 0.926, 0.813, 1.006, respectively, p=0.47). Conclusions: There are urban-rural disparities in access to AC independent of patients’ DD to CC. These disparities do not seem to alter patients’ SO. [Table: see text]
The Man Did Fine, but What About the Wahoo?
Authors: Gregory R. Hack
Journal: JAMA (1992)

<h3>To the Editor.</h3> —An axiom used by the media states that it is news only if "man bites dog." We are presenting a case of "fish bites man," which was given prominent local news coverage. A 69-year-old man was fishing off the Mexican coast of Baja California, when a wahoo, approximately 150 cm long and weighing 22.5 kg, jumped from the water and bit him on his nondominant left upper extremity. The two sites of injury were a superficial laceration to the ulnodorsal border of the hand and a 10-cm laceration to the distal one third of the dorsal forearm. Emergency first aid treatment was given at a Mexican clinic in Baja California, and further treatment was performed at our hospital. At the time of surgery, the tendon of the extensor carpi ulnaris was found to have a 2-cm segmental defect and there was laceration of the extensors of the
Costs and Effects of Inhaled Corticosteroids and Bronchodilators in Asthma and Chronic Obstructive Pulmonary Disease
Authors: Maureen P. M. H. Rutten-Van Mölken, Eddy K. A. Van Doorslaer, Margreet C. C. Jansen, Huib A. M. Kerstjens, Frans F. H. Rutten
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

The objective of this study was to determine the costs and effects of combined bronchodilator and anti-inflammatory therapy. In a 2.5-yr randomized controlled study, combined β2-agonist/corticosteroid therapy (BA + CS) and combined β2-agonist/anticholinergic therapy (BA + AC) were compared with β2-agonist/placebo therapy (BA + PL). Included in the study were 274 patients 18 to 60 yr of age with moderately severe obstructive airways disease. The main clinical endpoints were lung function, hyperresponsiveness, restricted activity days, and symptom-free days. The economic endpoints were the costs of health care utilization. Compared with BA + PL, BA + CS led to significant improvements in FEV1, PC20, and symptom-free days. BA + AC did not differ from BA + PL in this respect. The respective annual acquisition costs of BA + CS, BA + AC, and BA + PL were 532 US$, 277 US$, and 156 US$. Thus, BA + CS costs 376 US$ more than BA + PL. However, compared with BA + PL therapy, BA + CS led to statistically significant savings in other health care costs of about 175 US$ (95% CI from 46 to 303 US$). Thus, more than half of the additional costs of adding the inhaled corticosteroid are compensated for by a reduction in the costs of other health care services. Overall, inhaled corticosteroids lead to a small but net increase in health care costs of 201 US$ per patient per year. The incremental cost-effectiveness ratio of BA + CS compared with BA + PL ranges from 200 US$ per 10% increase in FEV1 to 5 US$ per symptom-free day gained. In order to reach net societal savings the economic benefits of increased productivity due to inhaled corticosteroids have to be valued higher than 42 US$ per day. No significant differences in health care costs were found between the BA + AC and BA + PL groups. It can be concluded that the addition of an inhaled corticosteroid to a β2-agonist leads to significant benefits in respiratory function and restricted activity days, which seem to be worth the relatively low additional health care costs, whereas addition of an anticholinergic agent appears expensive and of no long-term value.
Corticosteroid Therapy for Severe Sepsis and Septic Shock—Reply
Authors: Djillali Annane
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOMESTIC CORRESPONDENCE.
Authors: Otto Hauberg-Knudsen
Journal: JAMA (1884)

<h3>BIOGRAPHICAL SKETCH OF PROFESSOR P. L. PANUM., M.D.,</h3> President of the Eighth International Medical Congress held at Copenhagen, Denmark, 1884, in the month of August, beginning on the 10th and and ending on the 16th. Professor Peter Ludwig Panum was born on the 19th of December, 1820, in a small town called Ronne, on the Danish island Bornholm, in the Baltic Sea, where his father was a physician. In the year 1840 young Panum was sent to the University of Kiel, and from there went to the University of Copenhagen, where he in 1845 took his degree. As a student he already lectured with great success, and in consequence of his deep devotion to the study of the physiological branches of the science, he commanded universal attention. In 1846 when almost the whole population of the Faroe islands was suffering from the measles, Panum went thither by order of the Danish government, and during his six months' sojourn
Personal Use of Drug Samples by Physicians and Office Staff
Authors: John T. Chiu
Journal: JAMA (1997)

<h3>To the Editor.</h3> —If the agony of Dr Westfall and colleagues<sup>1</sup>over personal use of drug samples were indeed pertinent, Shen Nung, who purportedly founded Chinese herbal medicine by testing hundreds of potentially medicinal plants, would have been the first known offender.<sup>2</sup>It is naive to believe that such practice, even if adopted universally by all health care professionals, will make a quark of difference in drug cost. If Westfall et al care to probe further, they will find that a drug's price is more closely related to that of its closest competitors and bears little relationship to its actual manufacturing cost. In fact, these same companies can still make a profit by selling their products at a fraction of the domestic price just a few paces from our borders. No one should be so cynical as to believe that a physician would use a drug on himself or herself just
THE CLERGY AND THE MEDICAL PROFESSION; THE MEDICAL CODE A TONIC.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunology
Authors: Stanley F. Hampton
Journal: JAMA (1972)

For years the teaching of immunology in medical school curricula has been incorporated in the course of microbiology, since immunology in that era involved primarily a study of antibodies to infectious agents and anaphylaxis to foreign sera. During the past generation, however, the newer knowledge of the dynamics of the immune response and the delineation of immune globulins by immunoelectrophoresis, with the demonstrations of protective antibodies in IgG and reagins in IgE has established immunology as an autonomous subject rather than just a part of microbiology. Without losing sight of historical basic principles, the authors have presented the newer concepts of immunology and their clinical applications in this excellent book. The book includes a fascinating introductory chapter of Ehrlich's and Metchnikoff's humoral and cellular theories of antibodies. Subsequent chapters include detailed descriptions of the physical, chemical, and biologic properties of "immunogens" (the term preferred by the author over "antigens") and
Text-Book of Hygiene. A Comprehensive Treatise on the Principles and Practice of Preventive Medicine from an American Standpoint.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quinidine-induced agranulocytosis
Authors: E. V. Eisner
Journal: JAMA (1977)

In a 75-year-old man, agranulocytosis and septicemia developed after eight weeks of quinidine sulfate therapy. An IgG antibody requiring the presence of quinidine was shown by complement-dependent leukocytotoxicity and leukoagglutination reactions. The antibody did not cross-react with quinine and was active against WBCs obtained from normal subjects and from the patient himself. (<i>JAMA</i>238:884-886, 1977)
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
Authors: Eiji Shinozaki, Akihito Kawazoe, Yasutoshi Kuboki, Yoshito Komatsu, Tomohiro Nishina, Hiroki Hara, Satoshi Yuki, Kohei Shitara, Hideaki Bando, Daisuke Kotani, Koji Takahashi, Yuichi Mikamoto, Hiromi Hasegawa, Nami Hirano, Shogo Nomura, Yosuke Togashi, Hiroyoshi Nishikawa, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2018)

3530 Background: The anti–PD-1 antibody pembrolizumab provided an objective response rate of 28-57% in patients (pts) with Microsatellite Instability–High (MSI-H) metastatic colorectal cancer (mCRC) vs 0% in pts with Non-MSI-H. The WNT/β-catenin signaling has been reported to prevent anti-tumor immunity and promote resistance of anti-PD-1/PD-L1 antibodies. Furthermore, STAT3 has been known to be a key driver of the immune evasion. This study investigates efficacy and safety of the combination of BBI608, which blocks phosphorylated STAT3 and downregulates WNT/β-catenin signaling, with pembrolizumab in pts with mCRC. BBI608 480mg BID with pembrolizumab was determined as RP2D in the phase I part (Kawazoe A, et al. ASCO-GI 2018). Here, we present the preliminary results of the ongoing phase II part. Methods: Phase II part was composed of Cohort A (MSI-H) and Cohort B (Non-MSI-H). The main eligibility criteria was pts with mCRC not responded or intolerant to standard chemotherapies. Primary endpoint was Immune-related objective response rate (irORR) determined by irRECIST. Sample size for Cohort A with 10 pts was determined in an exploratory manner. In Cohort B, according to a null hypothesis and alternative hypothesis; irORR = 5% and 20%, estimating required sample size was 40 pts with a one-sided alpha of 5% and power of 90%. Results: From Feb 2017 to January 2018, 10 pts were enrolled in Cohort A, and 37 pts in Cohort B. As of October 2017, tumor response was evaluated in 3 pts of Cohort A and 25 pts of Cohort B, respectively. Two out of the 3 pts in Cohort A showed confirmed partial response. Among 12pts with right-sided colon in Cohort B, one patient showed confirmed partial response with remarkable decline of CEA level, and two pts showed stable disease lasting more than 16 weeks. Immunohistochemistry before treatment demonstrated the high expressions of PD-L1, CD8, and MHC-class I in the tumor samples from the patient with partial response. No severe or unexpected adverse events occurred up to the present. Conclusions: BBI608 with pembrolizumab showed preliminary efficacy signals with acceptable toxicity for MSI-H as well as Non-MSI-H mCRC pts with right-sided primary. Clinical trial information: NCT02851004.
VOLUNTEER MEDICAL SERVICE CORPS
Authors: None J. C. C.
Journal: JAMA (1918)

<h3>FROM IOWA</h3><h3>To the Editor:</h3> —I wish to thank you for the information concerning the Volunteer Medical Service Corps. I do not like the methods pursued. The circular letter received with the application blank was an imperative one, saying. "Sign this and return at once." Another thing that has crept in is the signing of this blank by men over age not acceptable under any circumstances, and to put the very few like myself who did not sign the blank in a "slacker" minority. This, with the newspaper publicity, makes conditions both trying and embarrassing. I resent being put in a situation whereby those who are too old or physically incapacitated who can flaunt a button and use it as a whip to compel me to do something that, as you say, is "of indefinite and undeterminate value to the welfare of the nation." I do not approve of stampede
Arthur Richardson: dean of deans
Authors: P. Gunby
Journal: JAMA (1979)

Up on the fourth floor of an administration building on the campus of Emory University School of Medicine, Arthur Pawley Richardson, MD, has his mind on many things. Ranging from alumni activities to zoology requirements, these are things that a medical school dean must master for survival. Richardson apparently has mastered them, because he has survived. In fact, he has held his position longer than any of the other present deans of the nation's 124 medical schools. "One has to recognize," he reminds a visitor, "that everything changes. You can't continue to do things the same way. Maybe that's why I've survived." Richardson's desk is clear and the door is wide open, as it has been for all of the 23 years that he has been dean. Through it passes a stream of visitors in clinical coats, business suits, and the casual garb of medical students. Somehow, Richardson makes each
COMPARATIVE PATHOLOGY.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Experimental Use of Human Beings
Authors: J. R. E.
Journal: Annals of Internal Medicine (1966)

Editorials1 August 1966The Experimental Use of Human BeingsJ. R. E.J. R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-2-371 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe art of medicine, in which the healer enters compassionately into the hopes and fears of the patient, has come down from the misty past of more than 2 millenia and was never more important to the practice of medicine than it is today (1). The science of medicine, which now gives the physician such great power to control disease and to influence the fate of his patient, has had a much more recent origin in the last 4 centuries of the Scientific Revolution and its methodology. The essence of the scientific method is the experiment: the inductive and deductive...References1. BURGESSBURGESS AMAM: Caring for the patient—a trice told tale. New Eng. J. Med. 274: 1241, 1966. CrossrefMedlineGoogle Scholar2. LADIMERNEWMAN IRW (editors): Clinical Investigation in Medicine: Legal, Ethical and Moral Aspects. An Anthology and Bibliography. Law-Medicine Research Institute, Boston University, Boston, 1963, p. 517, [Reviewed in the Ann. Intern. Med. 62: 628, 1965]. Google Scholar3. BEECHER HK: Ethics and clinical research. New Eng. J. Med. 274: 1354, 1966. CrossrefMedlineGoogle Scholar4. LANGER E: Human experimentation: New York verdict affirms patients' rights. Science 151: 663, 1966. CrossrefMedlineGoogle Scholar5. LEAR J: Experiments on people—the growing debate. Sat. Rev. July 2, 1966, p. 41. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIn Memoriam: J. Russell Elkinton, MD, MACP, FRCP(L); 1910–2002; Editor, Annals of Internal Medicine, 1960–1971Edward J. Huth, MD, Editor EmeritusJ. Russell Elkinton, M.D., M.A.C.P.: A TributeMARSHALL N. FULTON, M.D.Emerging Assets and Liabilities of a Committee on Human Welfare and ExperimentationREPORT OF THE AD‐HOC COMMITTEE ON RATIONALIZATION OF FACILITIES FOR ORGAN TRANSPLANTATION AND RENAL DIALYSIS 1 August 1966Volume 65, Issue 2Page: 371-373KeywordsFear ePublished: 1 December 2008 Issue Published: 1 August 1966 PDF downloadLoading ...
The ALBI Grade Provides Objective Hepatic Reserve Phenotyping across Each BCLC Stage of Hepatocellular Carcinoma
Authors: D.J. Pinato, R. Sharma, C. Yen, T. Arizumi, D. Bettinger, J.W. Jang, C. Smirne, Y.W. Kim, M. Kudo, J. Howell, R. Ramaswami, M.E. Burlone, V. Guerra, R. Thimme, M. Ishizuka, M. Pirisi, J. Stebbing, K. Kubota, B.I. Carr
Journal: Journal of Hepatology (2016)